Illumina To Divest Grail After 5th Circ. Ruling
Biotech company Illumina said it will divest cancer testing firm Grail despite a U.S. appellate court vacating an order that had forced Illumina to unwind the $8 billion deal, amid opposition...To view the full article, register now.
Already a subscriber? Click here to view full article